Development of an APC and TP53-based Duplex Sequencing Assay to Positively Predict Colorectal Cancer Response to Anti-Egfr Therapy

EGFR inhibitor (EGFRi) therapies have been FDA-approved for metastatic colorectal cancer (CRC). However, extended RAS/RAF testing required in the drug labels, identifies only non-responders, and only 50